We use cookies to improve your experience, analyze site usage, and show relevant ads. Go to our Privacy Policy for details.
The call conveyed clear operational momentum: Q1 results beat expectations with organic growth, EPS upside (+11% YoY), improved gross margins (+80 bps), strong segment performance (MedSurg, Dental, HIS) and tangible progress on separation, SKU rationalization, and integration of Acera. Management reiterated multiyear savings (Transform for the Future $500M) and an intent to accelerate share repurchases while maintaining full-year guidance. The primary negatives are timing and separation-related volatility: reported sales declined -3% due to acquisition/divestiture impacts, tariff and inflationary headwinds ($100M–$120M range) remain, ERP cutover phasing will drive >$100M of order timing into Q2 that reverses in Q3, and certain legacy product lines (clinician productivity solutions) face double-digit declines. Overall, most issues are described as transitory or manageable via mitigation programs and the company emphasized accelerating margin expansion and product-driven growth, supporting a constructive outlook.
Management reiterated full‑year guidance while flagging key phasing and headwinds: they expect EPS toward the high end of the $6.40–$6.60 range, are targeting operating margin of 21.0%–21.5% (up 50–100 bps year‑over‑year), and are maintaining free cash flow guidance; they continue to assume tariffs of $100–$120 million and a ~100 bp FX tailwind to sales. They disclosed a Q2 ERP timing benefit of over $100 million of sales that will reverse mostly in Q3, and noted SKU rationalization (~100 bp drag in Q1, >50% complete, finishing by year‑end) and a $500 million Transform for the Future savings program. First‑quarter anchors included $2.0 billion sales (+2.1% organic, -3% reported), adjusted operating income $392 million (19.5% margin), gross margin 56.4% (+80 bps), EPS $1.48 (+11%), cash $561 million, net debt $4.5 billion, and they repurchased ~923,000 shares for $67 million with board authorization up to $1 billion; tax rate guidance remains 19.5%–20.5%, and the long‑range organic growth target remains 4%–5%.
Reported Q1 sales of $2.0 billion with organic sales growth of +2.1% and adjusted EPS of $1.48 (+11% YoY), both ahead of plan and Street expectations; company reiterated full-year organic sales and free cash flow guidance and now expects EPS toward the high end of $6.40–$6.60.
Gross margin of 56.4%, an improvement of +80 basis points YoY; adjusted operating income of $392 million and operating margin of 19.5%; company targets full-year operating margin of 21.0%–21.5% (up 50–100 bps vs prior year).
MedSurg: $1.2B sales, organic +1.2% (Advanced Wound Care +2.1%, Acera contributed $28M). Dental Solutions: $354M sales, organic +3.4%. Health Information Systems: $342M sales, organic +4.7% (strength in revenue cycle management and performance management).
Acera acquisition immediately contributed $28M to reported sales and integration is tracking to plan; company completed sale of P&F (purification and filtration) and continues active portfolio optimization.
Exited ~50% of transition service agreements (TSAs) and on pace to exit >90% by end of 2026; migrated ~75% of >1,200 system applications with successful ERP cutover in Asia Pacific (including China); reduced distribution centers to 54 worldwide.
More than 50% through SKU rationalization (100 bps headwind in Q1, expected to finish by year-end); company expects ~20 new product launches over next two years targeted at growth-driver areas to fuel future organic growth.
Multiyear program targeting $500 million of savings through system streamlining, automation, and global footprint optimization; program already delivering benefits and expected to deliver more meaningfully in 2027 and beyond.
Supply chain actions and ERP/distribution changes improved manufacturing performance and reduced backorders across the portfolio, supporting stronger customer fulfillment.
Ended Q1 with $561 million cash and equivalents, net debt of $4.5 billion; repurchased ~923,000 shares for $67 million in Q1 (share buyback authorization up to $1 billion); free cash flow ahead of expectations for the quarter.
RCM business and autonomous coding offering gaining traction (international expansion tailwind); management sees compelling economics (productivity gains, reduced FTE cost, improved revenue capture) and believes AI-enabled autonomous coding adoption will expand meaningfully over the strategic period.
Hello, and welcome to Solventum Corporation's first quarter fiscal year 2026 earnings call. All lines have been placed on mute to prevent any background noise. After the speakers' remarks, there will be a question and answer session. If you would like to ask a question during this time, please press 1 on your telephone keypad. I would now like to turn the conference over to Amy Wakeham, Senior Vice President of Investor Relations, Finance, and Communications. You may begin.
Thank you. Good afternoon, and welcome to Solventum Corporation's first quarter fiscal year 2026 earnings call. Joining me on today's call are Chief Executive Officer, Bryan Hanson, and Chief Financial Officer, Wayde McMillan. A replay of today's earnings call will be available later today in the Investor Relations section of our corporate website. The earnings press release and presentation are both available there now. During today's call, our discussion and any comments we make will be on a non-GAAP basis unless they are specifically called out as GAAP. The non-GAAP information discussed is not intended to be considered in isolation or as a substitute for the reported GAAP financial information. Please review the supporting schedules in today's earnings press release to reconcile the non-GAAP measures with the GAAP reported numbers.
Our discussion on today's call will include forward-looking statements including, but not limited to, expectations about our future financial and operating performance. These statements are made based on reasonable assumptions; however, our actual results could differ. Ple...